- Will I still be able to get my prescription medicines and medical products?
- Should I keep ordering my repeat prescriptions and taking my medicines as normal?
- Should I ask my GP for a larger or longer prescription?
- Will I still get my medicine if I am on a clinical trial?
- Will any routine NHS operations be cancelled?
- What is being done to make sure medicines and medical products continue to be available?
- What medicines and medical products are being included in the stockpiles?
- Will information about specific medicines and medical products be made available?
- What about over-the-counter medicines and medical products?
- What about the supply of blood and blood products?
- What about vaccines?
- What about unlicensed medicines and specials?
Yes. The Government is working closely with the NHS and suppliers to make sure medicines and medical products continue to be available in all scenarios. Occasionally, however, the NHS does experience temporary shortages of specific medicines. If this happens, you will be prescribed the best alternative to your usual medication as is normal. This will ensure that your treatment continues as normal.
If there are any shortages of medicines after EU Exit, your doctor or pharmacist will advise you of the best alternative to treat your condition, as per normal.
This will typically be a different brand of medicine or perhaps lower strength medicines to make up the same dose. On rare occasions, it may mean a different medicine to do the same thing, but prescribers will be supported on how best to do that should it be necessary.
Yes. There is no need to change the way that you order prescriptions or take your medicines. Always follow the advice of GPs and other health professionals who prescribe your medicines and medical products. There are enough medicines and medical products to meet current needs but if patients order extra prescriptions, or stockpile, it will put pressure on stocks, meaning that some patients may not get the medicines they need.
No. GPs will continue to prescribe medicines and medical products as normal.
The NHS and the Government is working with organisations running clinical trials to ensure that research continues as normal in the coming months. They have encouraged these organisations to consider their supply chains for clinical trials, and to ensure appropriate supplies of trial drugs and medical products are in place.
Planning for EU exit has been developed in partnership between the Government and the NHS to try and make sure that there is as little impact upon the NHS as possible. The NHS will make every effort to prioritise care for patients in emergencies and minimise disruption to routine patient care.
The Department of Health and Social Care (DHSC) has been working closely with the NHS, pharmaceutical companies, suppliers of medical devices, and supply chains to make sure medicines and medical products continue to be available in the event of a no deal EU exit.
Since 2018, DHSC has been working with all pharmaceutical companies that supply prescription-only medicines and pharmacy medicines to the UK that come from, or through, the EU or European Economic Area (EEA). DHSC has been asking companies to ensure they have extra stocks available in the UK by 12 April 2019.
Where these medicines have a short shelf life, DHSC has asked companies to ensure that they can fly these medicines in from the EU in the event of no deal. The NHS Supply Chain organisation is holding extra stocks of medical products.
To ensure that there will be enough space available for extra stocks of medicines and medical products, the Government has secured extra warehouse space including refrigerated and controlled drug storage that companies can use to store products.
The Government has also put in place extra shipping for suppliers to use on a variety of routes to ease pressure on the short straits crossings to Dover and Folkestone. This includes capacity on ferries to Poole, Portsmouth, Plymouth, Immingham and Felixstowe. The Government has agreed that medicines and medical products will be prioritised on these alternative routes.
The stockpiling programme is for medicines and medical products that would require a prescription or that you would usually get under supervision from a pharmacist, and that are either made in the EU or contain ingredients or components that are made in the EU.
The NHS and DHSC will be monitoring the medicines and medical products supply chain very carefully and we have well-established mechanisms to deal with supply issues when they do arise.
DHSC circulates regular updates about supply issues affecting medicines used in primary care and secondary care to the NHS, including to clinical commissioning groups (CCGs), hospitals and other secondary care providers. DHSC also liaises with specialist clinical groups, patient groups and other relevant networks to share information about supply issues that may affect specific patient groups.
There are existing systems in place to cascade messages quickly to the NHS and others for patient safety alerts, important public health messages and other safety critical information and guidance. If a specific medicine shortage emerges then prescribers and pharmacies will be quickly alerted to the situation and advised accordingly.
Pharmacy medicines, which can be bought over the counter from a pharmacy are covered in our stockpiling plans. General sales medicines and medical products, which can be sold in general retail outlets without the supervision of a pharmacist are not included in this stockpiling work because there are multiple alternatives available should any of these medicines and medical products be subject to a short-term supply disruption.
There are some medicines that are derived from blood plasma such as immunoglobulin, albumin, and clotting factors. As these are licensed medicines, they are included in the medicine supply plans.
The United Kingdom is largely self-sufficient in blood and blood components and does not routinely export or import these products, except for relatively small quantities of plasma which are imported by NHS Blood and Transplant for use in those born after 1996 as an agreed safety measure. In very special cases NHS Blood and Transplant do export or import very rare blood for urgent clinical need, usually in single unit quantities. DHSC is working closely with NHS Blood and Transplant, which is leading on the contingency planning for blood and blood components to ensure continuity of a safe blood supply.
Public Health England (PHE) manages significant stockpiles of vaccine for the national immunisation programme, as part of their business as usual planning. It is working closely with vaccine suppliers to ensure replenishment of these existing stockpiles continues in the event of supply disruption in the UK, for example, agreeing increases in supplier’s own UK stockpiles.
DHSC is also working to ensure that there are sufficient stockpiles of vaccines for other NHS and non-NHS uses i.e. uses outside of the national vaccination programmes such as for travel and occupational health purposes within its medicines contingency programme.
DHSC has met many unlicensed and specialist suppliers and asked them to ensure that by 12 April 2019 they have a minimum of six weeks additional supply in the UK in case of a no deal scenario. Other suppliers are also being contacted. In addition, unlicensed medicines and specials manufacturers are working to ensure sufficient ingredients in the UK to ensure continuity of supply. As with other medicines, unlicensed medicines will be prioritised in the Government’s agreed alternative.